Cardiff Oncology
CRDF
47 hedge funds and large institutions have $3.84M invested in Cardiff Oncology in 2017 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 9 closing their positions.
100% more call options, than puts
Call options by funds: $2K | Put options by funds: $1K
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
0.05% more ownership
Funds ownership: 0.15% → 0.2% (+0.05%)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
2% less funds holding
Funds holding: 48 → 47 (-1)
10% less capital invested
Capital invested by funds: $4.25M → $3.84M (-$416K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.46M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$320K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$304K |
| 4 |
EP
Elkhorn Partners
Omaha,
Nebraska
|
+$93.6K |
| 5 |
VF
Virtu Financial
New York
|
+$68.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$228K |
| 2 |
ECM
Element Capital Management
New York
|
-$166K |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
-$151K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$104K |
| 5 |
Morgan Stanley
New York
|
-$55.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Creative Planning
Overland Park,
Kansas
| – | -$9K | -104 | Closed |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| – | -$7K | -74 | Closed |
|
53
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$2K | -17 | Closed |
|
54
Wells Fargo
San Francisco,
California
| – | -$1K | -12 | Closed |
|
|
CG
55
Cutler Group
San Francisco,
California
| – | -$312 | -5 | -33% |
|
CRDF Hedge Fund Activity: Q3 2017 in Review
47 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q3 2017, worth a combined $3.84M — down 9.8% from $4.25M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CRDF positions and 9 closed out — a net gain of 1 holder — while 11 added to existing stakes and 11 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.46M. The largest seller was Goldman Sachs, cutting an estimated $228K.
- 47 institutional investors held Cardiff Oncology (CRDF) as of Q3 2017, down from 48 in Q2 2017.
- Funds reported $3.84M of Cardiff Oncology stock for Q3 2017, down 9.8% quarter-over-quarter.
- 10 funds opened new Cardiff Oncology positions in Q3 2017 and 9 closed out, a net change of +1 holder.
- The largest Cardiff Oncology buyer in Q3 2017 was Sabby Management, an estimated $1.46M added.
- The largest Cardiff Oncology seller in Q3 2017 was Goldman Sachs, an estimated $228K sold.
Based on aggregated 13F filings for Q3 2017.